<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(13)</volume><submitter>Rajesh Y</submitter><pubmed_abstract>Glioblastoma (GBM) is the most common primary brain tumor and is invariably fatal. Heat shock proteins (HSPs) provide protein signatures/biomarkers for GBM that afford potential as targets for developing anti-GBM drugs. In GBM, elevated expression of hypoxia inducible factors under the influence of Ets family proteins significantly promotes the expression of HSPs. RNAseq analysis identified HSPB1 as a prominent upregulated HSP in GBM and in radiation resistant/temozolomide resistant (radio/TMZR) GBM. Here, we established friend leukemia integration 1 (Fli-1), a member of Ets family to be playing a transcriptional regulatory role on the HSPB1 gene. Fli-1 binds to nucleotide residues GGAA at binding sites 3, 6 and 7 in the 5-kb upstream region of HSPB1. Fli-1 has been linked to oncogenic transformation with upregulation in radio/TMZR GBM. Overexpression of Fli-1 in GBM promotes resistance, whereas Fli-1 knockdown in radio/TMZR GBM cells suppresses resistance. We identify the underlying molecular mechanisms of Fli-1-mediated regulation of HSPB1 that drive extracellular matrix remodeling and epithelial to mesenchymal transition in radio/TMZR GBM cells. This study uncovers Fli-1 as a potential therapeutic target for combating radiation and temozolomide resistance in GBM.</pubmed_abstract><journal>Oncotarget</journal><pagination>1097-1108</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7138161</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Transcriptional regulation of HSPB1 by Friend leukemia integration-1 factor modulates radiation and temozolomide resistance in glioblastoma.</pubmed_title><pmcid>PMC7138161</pmcid><pubmed_authors>Banik P</pubmed_authors><pubmed_authors>Pal I</pubmed_authors><pubmed_authors>Saha A</pubmed_authors><pubmed_authors>Fisher PB</pubmed_authors><pubmed_authors>Das S</pubmed_authors><pubmed_authors>Das SK</pubmed_authors><pubmed_authors>Emdad L</pubmed_authors><pubmed_authors>Borkar SA</pubmed_authors><pubmed_authors>Mandal M</pubmed_authors><pubmed_authors>Rajesh Y</pubmed_authors><pubmed_authors>Sardana H</pubmed_authors><pubmed_authors>Biswas A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transcriptional regulation of HSPB1 by Friend leukemia integration-1 factor modulates radiation and temozolomide resistance in glioblastoma.</name><description>Glioblastoma (GBM) is the most common primary brain tumor and is invariably fatal. Heat shock proteins (HSPs) provide protein signatures/biomarkers for GBM that afford potential as targets for developing anti-GBM drugs. In GBM, elevated expression of hypoxia inducible factors under the influence of Ets family proteins significantly promotes the expression of HSPs. RNAseq analysis identified HSPB1 as a prominent upregulated HSP in GBM and in radiation resistant/temozolomide resistant (radio/TMZR) GBM. Here, we established friend leukemia integration 1 (Fli-1), a member of Ets family to be playing a transcriptional regulatory role on the HSPB1 gene. Fli-1 binds to nucleotide residues GGAA at binding sites 3, 6 and 7 in the 5-kb upstream region of HSPB1. Fli-1 has been linked to oncogenic transformation with upregulation in radio/TMZR GBM. Overexpression of Fli-1 in GBM promotes resistance, whereas Fli-1 knockdown in radio/TMZR GBM cells suppresses resistance. We identify the underlying molecular mechanisms of Fli-1-mediated regulation of HSPB1 that drive extracellular matrix remodeling and epithelial to mesenchymal transition in radio/TMZR GBM cells. This study uncovers Fli-1 as a potential therapeutic target for combating radiation and temozolomide resistance in GBM.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Mar</publication><modification>2021-02-20T14:12:10Z</modification><creation>2020-05-22T17:11:49Z</creation></dates><accession>S-EPMC7138161</accession><cross_references><pubmed>32284788</pubmed><doi>10.18632/oncotarget.27425</doi></cross_references></HashMap>